SODIUM LAURYL SULFATE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
265.0 3.4 0 4 66.0 12 1.0
CAS
151213
UNII
368GB5141J
SYNONYMS
ZINC ID(s)
Availability
Present in 57 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02227069 2014-09-01 Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers Phase 1 Active, Not Recruiting
NCT02256930 2014-09-01 Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers Phase 1 Active, Not Recruiting
NCT02198963 2014-07-01 21 Day Cumulative Skin Irritation of RUT058-60 Phase 1 Completed
NCT02160574 2014-06-01 Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA Phase 1 Completed
NCT02169154 2014-06-01 A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel Phase 1 Completed
NCT02168478 2014-06-01 Neo-Synalar Modified 48 Hour Patch Test Phase 4 Completed
NCT02117752 2014-04-01 Dermal Tolerability of Dapsone Gel in Healthy Volunteers Phase 1 Completed
NCT02062073 2014-01-01 Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion Phase 1 Completed
NCT02061813 2014-01-01 Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion Phase 1 Completed
NCT01816529 2013-03-01 Topical Safety Study of Topical Diltiazem Hydrochloride Phase 1 Active, Not Recruiting
NCT01821274 2013-03-01 A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design Phase 1 Active, Not Recruiting
NCT01771822 2013-01-01 Ibuprofen 5% Topical Gel CIPT Phase 1 Completed
NCT01787448 2013-01-01 RIPT of Ibuprofen Topical Gel Phase 1 Completed
NCT01430312 2011-09-01 21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation Phase 1 Completed
NCT00781664 2008-10-01 Cumulative Irritation Test Phase 1 Completed
NCT00680095 2007-01-01 Cumulative Irritation Test Phase 1 Completed
NCT02259868 2005-06-01 Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects Phase 1 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Buccal Tablet 5.18MG
Buccal Tablet, Extended Release 5.18MG
Buccal/sublingual Tablet 1.1MG
Dental Gel 1.47%
Dental Paste
Oral Capsule 21.6MG
Oral Capsule (immed./comp. Release), Hard Gelatin 3.6MG
Oral Capsule, Delayed Action 2MG
Oral Capsule, Delayed Action, Coated, Hard Gelatin 2MG
Oral Capsule, Delayed Action, Enteric Coated
Oral Capsule, Delayed Release 1MG
Oral Capsule, Enteric Coated Pellets 0.6MG
Oral Capsule, Extended Release 16.67MG
Oral Capsule, Hard Gelatin 7MG
Oral Capsule, Soft Gelatin 96MG
Oral Capsule, Sustained Action 9.47MG
Oral Capsule, Sustained Action, Hard Gelatin 1.7MG
Oral Dispersible Tablet 8.4MG
Oral Drops
Oral Granule
Oral Powder, For Inhalation
Oral Powder, For Suspension 0.07%
Oral Suspension 0.15%
Oral Tablet 51.69MG
Oral Tablet (immed./comp. Release), Coated 1MG
Oral Tablet (immed./comp. Release), Film Coated 0.98MG
Oral Tablet (immed./comp. Release), Uncoated, Chewable 5MG
Oral Tablet, Coated 5.2MG
Oral Tablet, Delayed Action 1.64MG
Oral Tablet, Delayed Action, Enteric Coated 8.09MG
Oral Tablet, Delayed Release 0.0002MG
Oral Tablet, Extended Release 51.69MG
Oral Tablet, Film Coated 12MG
Oral Tablet, Multilayer, Extended Release 0.8MG
Oral Tablet, Orally Disintegrating 2MG
Oral Tablet, Sustained Action 20.62MG
Oral Tablet, Sustained Action, Coated 10.5MG
Oral-28 Tablet 0.65MG
Sublingual Tablet 0.02MG
Topical Emulsion, Cream 2.5%
Topical Lotion 0.5%
Topical Ointment 1%
Topical Shampoo
Topical Shampoo, Suspension 40%W/V
Topical Sponge
Vaginal Cream, Emulsion, Sustained Release 0.3%
Vaginal Emulsion, Cream 0.33%
Vaginal Insert 5MG
Vaginal Tablet 5MG

More Information

Usage Over Time

Comments